A CALLY index less than 0.45 was independently associated with a 3.56-fold increased risk of 1-year mortality after TAVI.
Observational (n=532)
No
Does the baseline CALLY index predict 1-year mortality in patients undergoing TAVI?
The CALLY index is a simple, easily calculated immunonutritional biomarker that provides strong, independent prognostic value for 1-year mortality after TAVI, outperforming traditional surgical risk scores.
Effect estimate: OR 3.556 (95% CI 95% CI 2.123–5.636)
Absolute Event Rate: 36.4% vs 6.6%
p-value: p=<0.001
Objectives: Systemic inflammation, malnutrition, and immune dysregulation have emerged as important determinants of long-term outcomes after transcatheter aortic valve implantation (TAVI). The C-reactive protein–albumin–lymphocyte (CALLY) index is a novel immunonutritional biomarker that integrates these pathophysiological domains; however, its prognostic value in TAVI patients has not yet been investigated. This study aimed to evaluate the association between the CALLY index and 1-year mortality after TAVI. Methods: This retrospective observational study included 532 consecutive patients who underwent TAVI at a tertiary-care center between 2014 and 2023. Baseline laboratory parameters were obtained before the procedure, and the CALLY index was calculated as (albumin × lymphocyte count)/(C-reactive protein × 10). The primary endpoint was 1-year mortality. Receiver operating characteristic (ROC) curve analysis was performed to assess the discriminative ability of the CALLY index and conventional surgical risk scores. Multivariable regression analyses were used to identify independent predictors of mortality. Results: During the 1-year follow-up period, 85 patients (15.9%) died. Patients who died had significantly lower baseline CALLY index values compared to survivors (p < 0.001). The CALLY index demonstrated good discriminative performance for 1-year mortality (AUC: 0.797), outperforming EuroSCORE II (AUC: 0.705) and the Society of Thoracic Surgeons (STS) score (AUC: 0.619). A CALLY cut-off value of 0.45, derived using Youden’s index, was associated with a more than threefold increased risk of mortality. In multivariable analysis, the CALLY index remained independently associated with 1-year mortality, along with EuroSCORE II and more than mild mitral regurgitation. Conclusions: The CALLY index is a strong and independent predictor of 1-year mortality after TAVI and provides incremental prognostic value beyond conventional surgical risk scores. Given its simplicity and reliance on routinely available laboratory parameters, the CALLY index may serve as a practical tool for long-term risk stratification in patients undergoing TAVI.
Süygün et al. (Mon,) conducted a observational in Adults with severe symptomatic aortic stenosis undergoing transcatheter aortic valve implantation (n=532). Baseline C-reactive protein–albumin–lymphocyte (CALLY) index assessment vs. Higher CALLY index (≥0.45) vs. lower CALLY index (<0.45) was evaluated on 1-year all-cause mortality after transcatheter aortic valve implantation (OR 3.556, 95% CI 95% CI 2.123–5.636, p=<0.001). A CALLY index less than 0.45 was independently associated with a 3.56-fold increased risk of 1-year mortality after TAVI.